Tinnitus Clinical Trial
Official title:
Clinical Trial: Intratympanic Injection of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity
Verified date | February 2023 |
Source | Centre Hospitalier Universitaire Saint Pierre |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the efficacity of N-acetylcystein against Cisplatin-induced ototoxicity.
Status | Terminated |
Enrollment | 19 |
Est. completion date | September 3, 2023 |
Est. primary completion date | May 3, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - = 18-year-old - Patients suffering from a neoplastic disease for which treatment protocol includes Cisplatin. Exclusion Criteria: - Women of childbearing potential pregnant or with intention to become pregnant within the trial duration - Women who are breastfeeding - Pathological findings on otoscopy that do not allow safe intratympanic drug delivery. - Conductive hearing loss > 20dBHL - Meniere disease - Medical history of sudden hearing loss - Sensoryneural Hearing loss (SNHL) with mean = 40dbHL Pure Tonal Audiometry (PTA) |
Country | Name | City | State |
---|---|---|---|
Belgium | CHU Saint-Pierre | Brussels |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire Saint Pierre |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Apparition of ototoxicity | the apparition of ototoxicity as defined by the International Common Terminology Criteria for Adverse Events (CTCAE), version 5:
A Threshold shift of 15 - 25 decibel (dB) averaged at 2 contiguous test frequencies in at least one ear and/or the apparition of a tinnitus (not previously present). |
6 month after last injection | |
Secondary | Evaluate the apparition of ototoxicity defined by the inclusion of high frequency audiometry (Tune Grading System) | the apparition of ototoxicity as defined by the International Common Terminology Criteria for Adverse Events (CTCAE), version 5:
A Threshold shift of 15 - 25 dB averaged at 2 contiguous test frequencies in at least one ear and/or the apparition of a tinnitus (not previously present). |
6 month after last injection | |
Secondary | Hearing quality of life: Evaluation of the Impact of Hearing Loss in Adults ERSA | Evaluation of the Impact of Hearing Loss in Adults (ERSA) For each question, the score of 0 means maximal difficulties, the sore of 10 means ideal situation Formulation is uniform, with no inversions: 0 always corresponds to maximal difficulty and 10 to an ideal situation, so that the lower the score the greater the impact of hearing loss on quality of life. Maximum score is 200 for respondents in work and 150 for those not in work or in retirement. | 6 month after last injection | |
Secondary | Hearing quality of life: Tinnitus Handicap Index (THI) | Tinnitus Handicap Index (THI) score Range : 0 to 100. Higher scores mean a worse outcome. | 6 month after last injection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05963542 -
Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia
|
N/A | |
Recruiting |
NCT04987502 -
Virtual Reality and Subjective Tinnitus
|
N/A | |
Recruiting |
NCT04404439 -
Treatment of Tinnitus With Migraine Medications
|
Phase 4 | |
Recruiting |
NCT05533840 -
Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
|
||
Completed |
NCT03552302 -
Effects of Yoga Exercise on Participates With Tinnitus
|
||
Enrolling by invitation |
NCT02617953 -
Objective Diagnosis Method and Efficacy of Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus
|
N/A | |
Completed |
NCT02974543 -
Somatosensory Stimulation to Alleviate Tinnitus
|
N/A | |
Completed |
NCT02269839 -
A Feasibility Study Assessing the Effectiveness of rTMS in Tinnitus
|
N/A | |
Withdrawn |
NCT01663467 -
Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy
|
N/A | |
Completed |
NCT01929837 -
Tinnitus rTMS 2013
|
N/A | |
Completed |
NCT01857661 -
The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial
|
N/A | |
Completed |
NCT01927991 -
Internet-based Self-help for Tinnitus: The Role of Support
|
N/A | |
Completed |
NCT01480193 -
New Therapy for Patients With Severe Tinnitus
|
N/A | |
Terminated |
NCT01412918 -
Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression
|
N/A | |
Completed |
NCT00748475 -
Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus
|
N/A | |
Completed |
NCT00371436 -
Progressive Intervention Program for Tinnitus Management
|
N/A | |
Completed |
NCT00733044 -
Cost-effectiveness of Multidisciplinary Management of Tinnitus
|
N/A | |
Active, not recruiting |
NCT05518682 -
Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus
|
N/A | |
Recruiting |
NCT05212298 -
Effects of Herbal Sleep Formula on Patients With Insomnia and Tinnitus
|
N/A | |
Completed |
NCT06025097 -
Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
|
Early Phase 1 |